Unknown NA INTERVENTIONAL 2-arm NCT04987554

Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2

Modulation of the Immune Response by AM3 Glycoconjugate.

Sponsor: Instituto de Salud Carlos III

Interventions Placebo glycophosphopeptical AM3

Updated 4 times since 2021 Last updated: Jul 29, 2021 Started: Apr 1, 2021 Primary completion: Dec 31, 2021 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates SARS-CoV-2 Infection and is currently ongoing. Instituto de Salud Carlos III leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Sep 2021 — Aug 2023 [monthly]

Recruiting NA

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto de Salud Carlos III
Sanidad de Castilla y León
University of Valladolid

Data source: University of Valladolid

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Soria, Spain